研飞客户端支持数万种期刊查询，助你在阅读和写作中随时了解期刊动态
Expert Opinion on Therapeutic Patents
| 短名 | Expert Opin. Ther. Pat. |
| Journal Impact | 5.46 |
| 国际分区 | PHARMACOLOGY & PHARMACY(Q1) |
| 期刊索引 | SCI Q1中科院 2 区 |
| ISSN | 1354-3776, 1744-7674 |
| h-index | 88 |
| 国内分区 | 医学(2区)医学药物化学(2区)医学药学(2区) |
《Expert Opinion on Therapeutic Patents》（ISSN 1354-3776 [印刷版]，1744-7674 [电子版]）是一本国际同行评审的期刊，收录于MEDLINE，专注于近期药物专利的评论文章，旨在为未来的发展提供专家见解。编辑欢迎关于具有治疗潜力的化合物或应用的专利权利要求的评论，包括针对特定分子靶标的生物治疗药物和小分子药物，以及特定治疗领域的专利申请趋势。期刊还评估个别专利的目的，探讨与化学和生物权利要求及知识产权相关的问题。读者包括制药行业的科学家、管理人员和决策者，以及与研发密切相关的其他专业人士。我们提供最新的两卷完整卷，供您免费访问14天。
期刊主页投稿网址阅读文献时，研飞即可帮你快速了解期刊，查询影响因子与分区，智能高亮期刊预警！
| 涉及主题 | 生物医学化学生物化学遗传学内科学药理学有机化学免疫学心理学物理计算生物学受体内分泌学核磁共振 |
| 出版信息 | 出版商: Taylor and Francis Ltd.，出版周期: Monthly，期刊类型: journal |
| 基本数据 | 创刊年份: 1991，原创研究文献占比: 16.33%，自引率:1.90%， Gold OA占比: 4.14% |
| 平均审稿周期 | 网友分享经验：较慢,6-12周 |
| 平均录用比例 | 网友分享经验：一般 |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
手工熬夜修改参考文献？研飞自动匹配期刊，一键轻松成稿，支持 Word/WPS
点击下方按钮，免费开启试用！
最新文章
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019-2023 update of the patent literature.
2024-10-4
A patent review of lactate dehydrogenase inhibitors (2014-present)
2024-10-2
Correction
2024-9-27
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)
2024-9-26
Pyruvate kinase modulators as a therapy target: an updated patent review 2018–2023
2024-9-16
MEK inhibitors in oncology: a patent review and update (2016 - present)
2024-9-14
Helicase-primase inhibitors for the treatment of herpes simplex virus infections – patent evaluation of WO2023/225162 from gilead sciences inc
2024-9-12
Patenting perspective of modulators of ClpP endopeptidase: 2019-present
2024-9-12
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present)
2024-9-11
Update on JNK inhibitor patents: 2015 to present
2024-9-2
An updated patent review of BRD4 degraders
2024-9-1
Trends in covalent drug discovery: a 2020-23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in fda-approved drugs
2024-9-1
Caspase inhibitors: a review on recently patented compounds (2016–2023)
2024-8-29
Tetrahydroisoquinolines – an updated patent review for cancer treatment (2016 – present)
2024-8-10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)
2024-8-9
SGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23)
2024-7-30
Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to date
2024-7-18
A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020—present
2024-7-16
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present)
2024-7-12
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)
2024-7-9
Therapeutic potential of boswellic acids: an update patent review (2016–2023)
2024-7-5
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)
2024-7-3
FAK inhibitors in cancer, a patent review - an update on progress
2024-7-1
An updated patent review on PD-1/PD-L1 antagonists (2022-present)
2024-6-21
Patent review of cannabinoid receptor type 2 (CB <sub>2</sub> R) modulators (2016-present)
2024-6-18
Recent advances in the development of P2Y <sub>14</sub> R inhibitors: a patent and literature review (2018-present)
2024-6-18
Inhibition of GTPase KRAS <sup>G12D</sup> : a review of patent literature
2024-6-17
A patent review on hypoxia-inducible factor (HIF) modulators (2021-2023)
2024-6-14
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review
2024-6-11
Management of <i>Neisseria gonorrhoeae</i> infection: from drug resistance to drug repurposing
2024-6-2
Fighting antibacterial drug resistance
2024-6-2
Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents
2024-5-24
Anticancer drugs: where are we now?
2024-5-9
Biomedical applications of prokaryotic carbonic anhydrases: an update
2024-5-3
PIM kinase inhibitors: an updated patent review (2016-present)
2024-5-3
A patent review of SHP2 allosteric inhibitors (2018-present)
2024-5-3
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021 - December 2023)
2024-5-3
An updated patent review of stimulator of interferon genes agonists (2021 – present)
2024-5-3
An updated patent review of TRPA1 antagonists (2020 – present)
2024-5-3
An insight into the last 5-year patents on <i>porphyromonas gingivalis</i> and <i>streptococcus mutans</i> , the pivotal pathogens in the oral cavity
2024-4-29
Recent trends and challenges to overcome <i>Pseudomonas aeruginosa</i> infections
2024-4-29
Biofilm and bacterial membrane vesicles: recent advances
2024-4-5
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018 – present)
2024-4-2
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)
2024-4-2
PCSK9 inhibitors: a patent review 2018-2023
2024-4-2
Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update
2024-4-2
HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents
2024-4-2
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019-June 2023
2024-4-2
Carbonic anhydrase and bacterial metabolism: a chance for antibacterial drug discovery
2024-3-20
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023)
2024-3-7
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远